Enterprise record
Alpha ID: alpha:company:6f05ca0c-a52c-469e-bd04-7efad28236e7Version: public-1
35 published Claims5 sources
The enterprise, in context.
Connect capital, control, accountability, and evidence.
Governance priorities
Capital allocationInspect reported performance, cash generation, and investment.Board accountabilityWho holds each mandate, and what evidence supports it?Ownership & votingSeparate economic interests from voting authority.Key Claims
Board and committees
Financial statements
Published financial observations retain their reported values, periods, and sources. Coverage may be partial; this is not a reconstructed complete financial statement.
All financials coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageControl and shareholders
Control and shareholders coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageCompensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAuditors, advisors and reporting
Auditors, advisors and reporting coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageLegal
Legal coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAI governance
AI governance coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageEvidence, history and coverage
Additional published Claims
Published evidence records
5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Oct 1, 2026
Supports 4 claims
- Legal Name: Sanofi · Claim reviewed: Oct 1, 2026
- Entity Status: Public listing published · Claim reviewed: Oct 1, 2026
- Published Fact: US · Claim reviewed: Oct 1, 2026
- Published Fact: Healthcare · Claim reviewed: Oct 1, 2026
Sanofi Board of Directors
official company source · Source published: Sep 1, 2026 · Retrieved: Sep 2, 2026
Supports 16 claims
- Leadership Role: Frédéric Oudéa: Chairman of the Board of Directors · Claim reviewed: Oct 1, 2026
- Leadership Role: Anne-Françoise Nesmes: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Antoine Yver: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Barbara Lavernos: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Belén Garijo: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Carole Ferrand: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Christel Heydemann: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Christophe Babule: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Clotilde Delbos: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Emile Voest: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Humberto De Sousa: Director representing employees · Claim reviewed: Oct 1, 2026
- Leadership Role: Jean-Paul Kress: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: John Sundy: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Lise Kingo: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Rachel Duan: Independent director · Claim reviewed: Oct 1, 2026
- Leadership Role: Wolfgang Laux: Director representing employees · Claim reviewed: Oct 1, 2026
Sanofi Executive Committee press release 21 July 2026
official company source · Source published: Sep 1, 2026 · Retrieved: Sep 2, 2026
Supports 9 claims
- Leadership Role: Belén Garijo: Chief Executive Officer · Claim reviewed: Oct 1, 2026
- Leadership Role: Brendan O'Callaghan: Executive Vice President, Manufacturing & Supply · Claim reviewed: Oct 1, 2026
- Leadership Role: François Roger: Executive Vice President, Finance · Claim reviewed: Oct 1, 2026
- Leadership Role: Jamie Haney: Executive Vice President, General Counsel · Claim reviewed: Oct 1, 2026
- Leadership Role: Manuela Buxo: Executive Vice President, Specialty Care · Claim reviewed: Oct 1, 2026
- Leadership Role: Paulo Fontoura: Executive Vice President, Head of Research & Development · Claim reviewed: Oct 1, 2026
- Leadership Role: Thomas Grenier: Executive Vice President, General Medicines · Claim reviewed: Oct 1, 2026
- Leadership Role: Thomas Triomphe: Executive Vice President, Vaccines · Claim reviewed: Oct 1, 2026
- Leadership Role: Véronique Jaillet: Executive Vice President, Chief People Officer, ad interim · Claim reviewed: Oct 1, 2026
Sanofi SA key executives
other · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026
Supports 5 claims
- Leadership Role: Natalie Bickford: Executive VP & Chief People Officer · Claim reviewed: Oct 1, 2026
- Leadership Role: Olivier Charmeil: Executive Vice President of General Medicines · Claim reviewed: Oct 1, 2026
- Leadership Role: Paul Hudson: CEO & Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Pierre Chancel: Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing · Claim reviewed: Oct 1, 2026
- Leadership Role: Roy Papatheodorou: Executive VP & General Counsel · Claim reviewed: Oct 1, 2026
CAC 40
index provider · Source published: Date unavailable · Retrieved: Sep 2, 2026
Supports 1 claim
- Index Membership: CAC 40 (PX1) · Claim reviewed: Oct 1, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Board and committees
- published
- Financial statements
- not observed
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed